Is it time to develop a "pathogenicity" score to distinguish long QT syndrome causing mutations from "background" genetic noise?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Association of QTc Interval and V4-S Wave With Appropriate ICD Therapy in Hypertrophic Cardiomyopathy.Frontiers in cardiovascular medicine · 2022
   Article
2. The Role of Pharmacogenetics in Atrial Fibrillation Therapeutics: Is Personalized Therapy in Sight?Journal of cardiovascular pharmacology · 2016
   Review
3. Atrial Fibrillation andCardiac electrophysiology clinics · 2014
   Article
4. SCN10A/Nav1.8 modulation of peak and late sodium currents in patients with early onset atrial fibrillation.Cardiovascular research · 2014
   Article
5. Impact of gene patents and licensing practices on access to genetic testing for long QT syndrome.Genetics in medicine : official journal of the American College of Medical Genetics · 2010
   Article

Corrections and comments

• Comment on
  Spectrum and prevalence of mutations from the first 2,500 consecutive unrelated patients referred for the FAMILION long QT syndrome genetic test.2009

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as